Caco-2
Sign in to saveAlso known as Caco 2, CACO2, Caco-2/ATCC, Caco-II
thumb|0x0px|Phase contrast [[micrograph of confluent Caco-2 cells]] Caco-2 (from Cancer coli, "colon cancer") is an immortalized cell line of human colorectal adenocarcinoma cells. It is primarily used as a model of the intestinal epithelial barrier. In culture, Caco-2 cells spontaneously differentiate into a heterogeneous mixture of intestinal epithelial cells. It was developed in 1977 by Jorgen Fogh at the Sloan-Kettering Institute for Cancer Research.
Research
27,665 papers- Caco-2 Cell Line Standardization with Pharmaceutical Requirements and In Vitro Model Suitability for Permeability Assays.Pharmaceutics · 2023
- The Caco-2 Model: Modifications and enhancements to improve efficiency and predictive performance.International journal of pharmaceutics · 2022
- Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers.Nature protocols · 2007
- Modulation of proliferation, apoptosis and inflammation of Caco-2 epithelial cells and THP-1 macrophage-like monocytes in LPS stimulated co-culture model.Bratislavske lekarske listy · 2021
- Caco-2 monolayers in experimental and theoretical predictions of drug transport.Advanced drug delivery reviews · 2001
via PubMed
Wikidata facts
- Image
- CaCo-2 cells after 21 days in culture.tif
Show 2 more facts
- Commons category
- Caco-2 cells
- exact match
- purl.obolibrary.org/obo/CLO_0050627
via Wikidata · CC0
~3 min read
Article
7 sectionsContents
- History
- Characteristics
- Research applications
- See also
- References
- Further reading
- External links
thumb|0x0px|Phase contrast [[micrograph of confluent Caco-2 cells]] Caco-2 (from Cancer coli, "colon cancer") is an immortalized cell line of human colorectal adenocarcinoma cells. It is primarily used as a model of the intestinal epithelial barrier. In culture, Caco-2 cells spontaneously differentiate into a heterogeneous mixture of intestinal epithelial cells. It was developed in 1977 by Jorgen Fogh at the Sloan-Kettering Institute for Cancer Research.
==History== The line was developed in 1977 by Jorgen Fogh at the Sloan-Kettering Institute for Cancer Research. The research application of Caco-2 cells was developed during the 1980s by Alain Zweibaum group at INSERM, France as well as Ismael Hidalgo, at the Borchardt laboratory, University of Kansas and Thomas J Raub and at the Upjohn Company. The first publication of the discovery of the spontaneous enterocyte like differentiation was published by Alain Zweibaum group in 1983.